ALLR — Allarity Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1860657 ·
Last close
$0.84
Market Cap
$13.38M
52W High
$1.84
52W Low
$0.77
ADV30
146,902
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,671,000 | -3,405,000 | 32,115,000 | 16,982,000 | 28,579,000 |
| Mar 2026 | 25,000 | — | -2,688,000 | -2,750,000 | 34,923,000 | 19,812,000 | 28,003,000 |
| Dec 2025 | 320,000 | — | -2,918,000 | -3,373,000 | 18,258,000 | 14,687,000 | 8,430,000 |
| Sep 2025 | 0 | — | -2,518,000 | -2,806,000 | 20,796,000 | 16,895,000 | 8,785,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,710,000
Investing CF
$-64,000
Financing CF
$21,810,000
CapEx
$-64,000
Dividends Paid
—
Buybacks
$-887,000
EPS Diluted TTM
$-0.72
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-136,352,000
Inventory
—
Receivables
$1,310,000
ST Investments
—
EBIT TTM
$-11,270,000
Pretax Income TTM
$-12,334,000
Interest Exp TTM
$1,064,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$345,000
EBITDA
$-10,801,000
Free Cash Flow
$-19,769,876
Enterprise Value
$20,479,648
Total Cash
$16,982,000
Total Debt
$22,286,000
Shares Out
15,910,724
Trailing EPS
$-0.79
Book Value
$0.52
ROE
-157.1%
ROA
-25.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 320,000 | -12,605,000 | -11,231,000 | 18,258,000 | 8,430,000 | 9,828,000 | -14,820,000 |
| Dec 2024 | 0 | -17,538,000 | -24,515,000 | 22,650,000 | 10,839,000 | 11,811,000 | -17,352,000 |
| Dec 2023 | 0 | -17,129,000 | -11,901,000 | 11,862,000 | 14,613,000 | -2,751,000 | -12,745,000 |
| Dec 2022 | 0 | -16,892,000 | -16,058,000 | 14,544,000 | 12,654,000 | 1,890,000 | -16,817,000 |
TTM Snapshot
Revenues TTM
$-114,000
NetIncome TTM
$-12,334,000
OpCashFlow TTM
—
Assets (Latest)
$32,115,000
Forward EPS
$-0.86
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TVRD | Tvardi Therapeutics, Inc. | $13.47M | $1.01 | — |
| SYBX | SYNLOGIC, INC. | $13.47M | $1.10 | — |
| ONCO | Onconetix, Inc. | $13.14M | $3.00 | — |
| AKTX | Akari Therapeutics Plc | $13.03M | $5.70 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $13.84M | $0.25 | — |
News headlines (Yahoo Finance, 1h cache)
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
2026-11-18 12:50 · Yahoo
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
2026-11-16 12:50 · Yahoo
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
2026-11-13 13:05 · Yahoo
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
2026-10-30 11:45 · Yahoo
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
2026-10-09 12:55 · Yahoo
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
2026-10-05 12:30 · Yahoo
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
2026-09-30 13:00 · Yahoo
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
2026-09-28 12:00 · Yahoo
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
2026-09-15 12:00 · Yahoo
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
2026-08-14 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.